Approximately 90% of cancer patients with metastatic breast, prostate, lung or colon cancers develop resistance to chemotherapy. Despite scientific advances, cancer treatment failure due to treatment resistance is a major problem in oncology.
OncoGenex Pharmaceuticals Inc. (OGXI) has focused its efforts on the development of therapeutics that target important mechanisms of cancer treatment resistance with the potential to improve treatment outcomes for patients with a variety of cancers.
The company was established in May 2000 as a spin-out from the Prostate Centre at Vancouver General Hospital and the University of British Columbia. It was co-founded by urologist Martin Gleave, MD, and Scott Cormack, OncoGenex' President and CEO, initially to develop and commercialize custirsen...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: